Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Bultas

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Casopis Lekaru Ceskych|December 3, 2010
[Pharmacogenetics in cardiovascular diseases therapy--treatment according guidelines or according the individual requirement?]Jan Bultas
Vnitrni Lekarstvi|September 25, 2020
Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment?Jan Bultas
Casopis Lekaru Ceskych|January 12, 2016
[Mountain sickness]Jan Bultas
Vnitrni Lekarstvi|February 19, 2015
[Anticoagulant therapy in secondary prevention of coronary events]Jan Bultas
Vnitrni Lekarstvi|October 25, 2022
Inflammation and vascular diseasesDebora Karetová, Jan Bultas
Vnitrni Lekarstvi|January 5, 2019
Anticoagulant therapy in the elderlyDebora Karetová, Jan Bultas
Vnitrni Lekarstvi|January 21, 2015
[Extended options of anticoagulant treatment in thromboembolism]Debora Karetová, Jan Bultas
Vnitrni Lekarstvi|September 18, 2020
Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?Debora Karetová, Josef Suchopár, Jan Bultas
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|May 19, 2004
Comparison of early diastolic mitral annular velocity and flow propagation velocity in detection of mild to moderate left ventricular diastolic dysfunctionTomas Palecek, Ales Linhart, Jan Bultas, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 21, 2007
The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry diseaseJoe T R Clarke, Michael L West, Jan Bultas, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Casopis Lekaru Ceskych|December 3, 2010
[Pharmacogenetics in cardiovascular diseases therapy--treatment according guidelines or according the individual requirement?]Jan Bultas
Vnitrni Lekarstvi|September 25, 2020
Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment?Jan Bultas
Casopis Lekaru Ceskych|January 12, 2016
[Mountain sickness]Jan Bultas
Vnitrni Lekarstvi|February 19, 2015
[Anticoagulant therapy in secondary prevention of coronary events]Jan Bultas
Vnitrni Lekarstvi|October 25, 2022
Inflammation and vascular diseasesDebora Karetová, Jan Bultas
Vnitrni Lekarstvi|January 5, 2019
Anticoagulant therapy in the elderlyDebora Karetová, Jan Bultas
Vnitrni Lekarstvi|January 21, 2015
[Extended options of anticoagulant treatment in thromboembolism]Debora Karetová, Jan Bultas
Vnitrni Lekarstvi|September 18, 2020
Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?Debora Karetová, Josef Suchopár, Jan Bultas
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|May 19, 2004
Comparison of early diastolic mitral annular velocity and flow propagation velocity in detection of mild to moderate left ventricular diastolic dysfunctionTomas Palecek, Ales Linhart, Jan Bultas, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 21, 2007
The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry diseaseJoe T R Clarke, Michael L West, Jan Bultas, et al.
Pageof 3